Digital health · Women’s hormonal health
Veera Health
An online clinic for polycystic ovary syndrome, built in Mumbai in 2020 and funded by Y Combinator and Sequoia Surge. Five years on the front door is a supplement shop, the patient apps are gone from both stores, and the operating revenue sits in a second company.
Four thousand answers
Towards the end of 2020 two sisters in Mumbai built a screening tool and pushed it out to women with polycystic ovary syndrome. Four thousand answered. One question asked what treatments they had already tried, and whether any had worked. Ninety per cent said the existing options had not.
That survey is the founding document of Veera Health. The pair launched the platform in January 2021, went through Y Combinator’s Winter 2021 batch, and six months later announced a $3 million seed round.
What they described was not an app in the wellness sense. It was a clinic that happened to run over a phone: a gynaecologist doing the first assessment, a dermatologist and a mental health specialist behind her, a nutritionist acting as the dedicated care manager, and a subscription that ran for months rather than a single consultation.
The gap it was aimed at
PCOS is a chronic endocrine condition. Independent reporting and the company both put its prevalence in India at roughly one in five women, with fewer than 30 per cent clinically diagnosed. Untreated it carries raised risk of infertility, type 2 diabetes and endometrial cancer. The symptom list is long enough that patients get routed to three or four unconnected specialists, none of whom sees the whole picture.
The legal frame arrived just before the company did. On March 25, 2020 the Board of Governors in supersession of the Medical Council of India framed the Telemedicine Practice Guidelines, added as Appendix 5 to the Indian Medical Council Ethics Regulations 2002. They require registered medical practitioners to complete a mandatory online course within three years of notification, and state that they do not cover consultations involving doctors or patients outside India. That last line matters, because Veera’s 2022 site said its protocol was “Reviewed by top medical doctors at University of Pennsylvania, USA,” and named Dr Anuja Dokras of the Penn Polycystic Ovary Syndrome Centre as an advisor. Advisory review is not a consulting licence. The clinicians who saw patients were Indian registered practitioners, and the site listed their degrees.
Two sisters, one diagnosis
Shobhita Narain was diagnosed with PCOS at 22. Shashwata studied data science at Yale and took an MBA at Wharton, then worked at Barclays Capital, Goldman Sachs and McKinsey. Shobhita read biology and psychology at Tufts and worked at GlaxoSmithKline, Accenture Life Sciences and UnitedHealth. Ministry of Corporate Affairs filings show both sisters and their father, Shyamendra Narain, appointed directors of Veera Healthcare Private Limited on the day it was incorporated, and again at a second company a year later.
From clinic to shelf
The clinic era ran from 2021 to 2023. In October 2022 the company launched an at home diagnostic package with Tata 1mg: samples collected at home, results in 48 hours, a 30 minute video consultation with a gynaecologist included, from Rs 2,900, in 24 Indian cities. A patient app followed. Subscriptions were listed at Rs 2,990 a month before discounts.
In March 2023 the direction changed. Veera launched Veera Wellness and a nutraceutical, VeeVital PCOS Support, a powder whose stated active ingredient is myo-inositol, at Rs 850 a box. By 2025 the company was describing itself to Mint as a platform focused on science backed supplements. Today veerahealth.com is a storefront. Tracxn classifies the business as a retailer of wellness supplements and expert led programs for women.
The apps did not survive the transition. On September 23, 2026 the Google Play listing for com.veerahealth.pcosapp and the Apple App Store listing id1585112134 both returned HTTP 404, while control requests to a listed app on each store returned 200.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Corporate registration | Veera Healthcare Private Limited, CIN U85100MH2020PTC337804, RoC Mumbai, incorporated Feb 17, 2020. Authorised capital Rs 1,00,000, paid up Rs 55,000. Three Narain directors from incorporation. Active. No registered charges. | Public record |
| Annual filings | Last AGM Sep 30, 2022 and last balance sheet Mar 31, 2022 for that entity, per an extract updated Oct 14, 2025. Tofler, updated Jul 13, 2026, still shows nothing later. | Public record |
| Where the trading sits | Audacious Healthcare Private Limited, CIN U72900MH2021PTC354364, incorporated Feb 2, 2021, same address, same three directors. Revenue Rs 7.6 crore for FY2024, up 76 per cent, accounts filed through Mar 31, 2025. Recorded as a subsidiary of Veera Inc. | Public record |
| Published evidence | No PubMed record for the company or its founders on PCOS. No ClinicalTrials.gov registration. The Clinical Trials Registry India search form could not be queried, so a CTRI entry cannot be ruled out. | Not found |
| The ASRM claim | veerahealth.com states the company is “the only women’s hormonal health company published in the American Society for Reproductive Medicine.” Searches of PubMed and the ASRM journal site returned no paper or abstract naming Veera. | Claim unverified |
| Outcome figures | Y Combinator page: 85 per cent feel in control after one month, four times more likely to complete treatment. The Better India, 2022: about 93 per cent. Tata 1mg page: three in four regularise periods within three months. None traces to a published study. | Company-stated |
| Diagnostics partnership | Tata 1mg package, Oct 2022: at home collection, 48 hour results, from Rs 2,900, in 24 cities. | Company-stated |
| Consumer signal | Trustpilot aggregate 3.4 out of 5 at an August 2025 capture, reviews split between praise and complaints about refunds. | Independent |
| Apps | Both store listings returned HTTP 404 on Sep 23, 2026. Controls returned 200. | Public record |
Read plainly: the clinical story is self reported. Every outcome number Veera has published came from its own members answering its own questions, and the three headline figures do not agree with one another. That is not unusual for a subscription care business, and it is not evidence. The corporate record is specific: an operating company that stopped filing accounts after FY2022, a sister company that kept filing and booked Rs 7.6 crore in FY2024, no secured debt on either, and a product line that has moved from consultations towards boxes.
What to watch
- Whether Veera Healthcare Private Limited files accounts for any year after FY2022, or is struck off.
- FY2025 and FY2026 numbers for Audacious Healthcare Private Limited, where the trading now sits.
- Any publication or CTRI registration behind the ASRM claim and the outcome percentages.
- Whether the coached programs return as a licensed clinical service or stay an upsell on supplements.
- Headcount. Tracxn recorded seven employees in February 2026 against 34 on the EPFO record in November 2024.
In their words
“The big issue around polycystic ovary syndrome is that there [are] a lot of different symptoms, and very often women take a long time to actually get diagnosed in the right manner”
Shashwata Narain, CEO and co-founder, TechCrunch, 2021 · Independent
“Many people didn’t believe PCOS was a real problem; they thought it was a figment of a woman’s imagination. There was little empathy, and even less understanding”
Shobhita Narain, COO and co-founder, Mint, 2025 · Interview
“We realized that if we’re experiencing this, millions of other women must be too. That’s when the switch flipped from venting to building.”
Shashwata Narain, Mint, 2025 · Interview
“We are a digital clinic. We bring everything that a woman needs to manage PCOS in one place.”
Shashwata Narain, The Better India, 2022 · Independent
“We have some of the best outcomes in the history of treatment. About 93 per cent of our members report feeling in control of their PCOS after doing the programme”
Shashwata Narain, The Better India, 2022 · Company-stated
“Within a matter of days Veera can diagnose, treat and bring peace of mind to those women suffering from PCOS who otherwise would still be seeking help or wondering where to even begin.”
Sean Doolan, partner, Global Founders Capital, seed release, 2021 · Investor, company release
“VeeVital is our step towards becoming a fully integrated women’s health platform, offering online lifestyle counselling and medical therapy, as well as evidence-based products”
Shobhita Narain, Financial Express, 2023 · Company-stated
Related companies
Sources
- Public recordMCA extract, Veera Healthcare Private Limited, U85100MH2020PTC337804
- Public recordCompany record, Veera Healthcare: capital, directors, charges
- Public recordMCA extract, Audacious Healthcare Private Limited, U72900MH2021PTC354364
- Public recordAudacious Healthcare report: filings, revenue, auditor, headcount
- Public recordLegal entities, funding and employee history
- Public recordEDGAR searches, PubMed searches and app store listing checks
- Public recordTelemedicine Practice Guidelines, Appendix 5 to the Ethics Regulations 2002
- IndependentVeera Health wants to help women in India navigate polycystic ovary syndrome
- IndependentMeet the sisters behind Veera Health, helping women fight PCOS
- InterviewSisters behind Veera Health share their journey
- IndependentSisters Offer Judgement-Free Healthcare to Women with PCOS
- IndependentVeera Health raises $3 million from Sequoia Surge, others
- IndependentVeera Health forays into nutraceuticals with VeeVital PCOS support
- IndependentVeerahealth customer reviews, aggregate 3.4 out of 5
- CompanyVeera Health raises US$3 million, seed release
- CompanyHome page, about page and PCOS Support product page
- CompanyClinician roster and Penn review line, 2022 site
- PartnerReverse PCOS with Veera Health, pricing and outcome claims
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
